BCM-95® (CURCUGREEN®), 07 Aug 2021

Saeede Saadati, Azita Hekmatdoost, Behzad Hatami, Asieh Mansour, Zahra Yari, Mehdi Hedayati, Amir Sadeghi

PMCID: PMC6347983

Aim: The aim of this study was to examine the effects of curcumin supplementation on hepatic fibrosis using different fibrosis
assessment methods.

Background: Nonalcoholic fatty liver disease (NAFLD) may progress to hepatic fibrosis. Detection of hepatic fibrosis should be measured by liver biopsy, which is an invasive method. Thus, some non-invasive methods are suggested.

Methods: Hepatic fibrosis was evaluated in forty-six patients with NAFLD before and three months after supplementation with 1.5 gram curcumin or placebo. Methods of assessments included fibroscan, and calculating non-invasive marker panel including FIB-4 (Fibrosis4), NFS (NAFLD fibrosis score), APRI (AST (Aspartate aminotransferase) Platelet Ratio Index), and BARD (body mass index, AST/ALT (Alanine aminotransferase ratio, diabetes).

Results: Fibrosis score was reduced significantly after curcumin supplementation using fibroscan (p<0.01), FIB-4 (p<0.05) and APRI (p<0.05) tests, while fibrosis score did not change significantly using BARD and NFS methods (p>0.05).

Conclusion: Our results revealed that fibroscan, FIB-4, and APRI are similar in assessment of hepatic fibrosis changes after curcumin
supplementation. Future studies with higher sample sizes are needed to confirm these results.

(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347983/)